Shield Therapeutics plc
Research Shield Therapeutics plc (1JS) on Bullrun: market cap EUR 50.27M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker1JS
- ExchangeF
- CountryUnited Kingdom
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyEUR
- Market capEUR 50.27M
- Financial periodFY2025
- RevenueUSD 49.70M
- Revenue growth54.4%
- Net income-USD 17.66M
- Free cash flow-USD 3.68M
- Gross margin46.4%
Valuation Snapshot
latest market cap is EUR 50.27M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 49.70M | -USD 17.66M | -USD 3.68M | 46.4% | -0.02 | USD 11.62M | USD 30.14M | -USD 15.08M |
| FY2024 | USD 32.18M | -USD 27.18M | -USD 9.19M | 46.4% | -0.03 | USD 6.52M | USD 26.37M | -USD 1.32M |
| FY2023 | USD 13.09M | -USD 33.29M | -USD 40.07M | 30.8% | -0.05 | USD 13.95M | USD 20.25M | USD 15.03M |
| FY2022 | USD 5.50M | -USD 49.79M | -USD 24.88M | 44.7% | -0.21 | USD 3.40M | USD 7.35M | USD 6.54M |
| FY2021 | USD 2.05M | -USD 26.56M | -USD 27.43M | 35.5% | n/a | USD 16.35M | USD 210.00K | USD 55.35M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-22 | EUR 50.27M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About Shield Therapeutics plc
Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru (ferric maltol), a non-salt based oral therapy for patients to treat the iron deficiency with or without anemia. Shield Therapeutics plc was incorporated in 2008 and is based in Gateshead, United Kingdom.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Shield Therapeutics plc's market cap?
Shield Therapeutics plc's market capitalization is EUR 50.27M.
What does Shield Therapeutics plc do?
Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru (ferric maltol), a non-salt based oral therapy for patients to treat the iron deficiency with or without anemia. Shield Therapeutics plc was incorporated in 2008 and is based in Gateshead, United Kingdom.